Open AccessEGFR first- and second-generation TKIs—there is still place for them in EGFR-mutant NSCLC patients
Author(s) -
Niki Karachaliou,
Manuel Fernández-Bruno,
Jillian Wilhelmina Paulina Bracht,
Rafael Rosell
Publication year - 2018
Publication title -
translational cancer research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.254
H-Index - 30
eISSN - 2219-6803
pISSN - 2218-676X
DOI - 10.21037/tcr.2018.10.06
Subject(s) - epidermal growth factor receptor , medicine , lung cancer , oncology , targeted therapy , immunotherapy , tyrosine kinase , mutant , erlotinib , cancer research , cancer , receptor , biology , gene , biochemistry
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom